MYGN Myriad Genetics Inc.

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the .

The highly competitive list is based on the analysis of survey responses from over 208,000 employees from Great Place To Work Certified™ companies in the health care industry. Earlier this year, , and  said the company is a great place to work – 29 percentage points higher than a typical U.S. company.

“This Fortune Best Workplaces in Health Care recognition is a testament to our commitment of inspiring a dynamic and diverse culture, where career development is prioritized, and all teammates have equal opportunity to grow and make a difference in our patients’ lives,” said Shereen Solaiman, chief people officer, Myriad Genetics. “We’re grateful for the passion, diverse talents and enthusiasm our teammates bring to the global Myriad workforce every day to help fulfill our mission of advancing the health and well-being for all.”

Great Place To Work determines its lists using its proprietary For All™ Methodology to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study, based on over 1.3 million survey responses and data from companies representing more than 7.5 million employees this year alone. Survey responses reflect a comprehensive picture of the workplace experience.

For more information about careers at Myriad, please visit: .

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

About the Fortune Best Workplaces in Health Care List

Great Place To Work selected the 2023 Fortune Best Workplaces in Health Care by gathering and analyzing confidential survey responses from more than 208,000 employees at Great Place To Work Certified organizations in the health care industry. Company rankings are derived from 60 employee experience questions within the . Great Place To Work determines its lists using its proprietary For All™ Methodology to evaluate and certify thousands of organizations in America’s largest ongoing annual workforce study. This year alone, 1.3 million survey responses were received and data from companies representing more than 7.5 million employees.

About Great Place To Work®

As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces™ List.

Follow Great Place To Work on , , and or visit and to learn more.

About Fortune

The Fortune mission is to change the world by making business better. We achieve that by providing trusted information, telling great stories, and building world-class communities. We measure performance by rigorous benchmarks. And we hold companies accountable. Our goal is to make Fortune a force for good through its second century and beyond. For more information, visit .

Media Contact:

Glenn Farrell

(385) 318-3718

Investor Contact:

Matt Scalo

(801) 584-3532



EN
06/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...

 PRESS RELEASE

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...

 PRESS RELEASE

Myriad Genetics Announces New $200 Million Credit Facility

Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...

 PRESS RELEASE

Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...

 PRESS RELEASE

Myriad Genetics Earns 2025 Great Place To Work Certification™

Myriad Genetics Earns 2025 Great Place To Work Certification™ SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company. “Our focus on inclusivity and caring makes this a great p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch